While there is no definitive cure for COVID-19 yet, scientists are leaving no stone unturned in the hopes of being able to formulate a possible treatment for the coronavirus. Recently, scientists saw that the antibodies present in llamas may be able to help in fighting the coronavirus.
COVID-19 is still affecting millions of people all over the world, with hundreds of thousands of people dying from the disease. Scientists from University of California, San Francisco are looking to harness the antibodies present among llamas to be able to formulate a cure or vaccine for the coronavirus. To do this, they created a molecule inspired by these antibodies and they found that it was actually very effective at inhibiting the coronavirus.
According to molecular biologist and biochemist Peter Walter, who is among the scientists who are working on the possible COVID-19 treatment from llama antibodies, “It binds the virus’ spike protein with unmatched affinity -- we’ve never seen anything like this in my lab before. It was absolutely beautiful to see.”
Despite the promising result, more tests and studies are needed to be done before it can really prove to be a cure for COVID-19. Nevertheless, this study suggests how far scientists are going to be able to come up with ways to combat the coronavirus.
So far, other drugs are used to treat the symptoms of COVID-19, and previously, the Food and Drug Administration of the US announced that the use of the drug remdesivir is now allowed for COVID-19 patients who are hospitalized. The agency issued a press release informing of their decision to give remdesivir to COVID-19 patients the green light.
“The FDA continues to make safe and potentially helpful treatments for COVID-19 available as quickly as possible in order to help patients. The data to support today’s action are encouraging. The data show that this treatment has the potential to help even more patients who are suffering from the effects of this devastating virus. We are working with drug developers to conduct randomized clinical trials to further study the safety and effectiveness of a number of potential therapies for COVID-19,” said FDA Commissioner Stephen Hahn.


FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Neuralink Expands Brain Implant Trials with 12 Global Patients
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 



